Gen Z’s expensive drug habit: More want brand-name meds that are 79% more expensive
Most Americans would prefer brand-name drugs—but end up buying generic versions because of the cost, new consumer research ...
Medicare Drug Coverage Is Often Inadequate—Here’s Why
She learned that she would have to try, and "fail," on two other drugs before Medicare would cover the new one.
Think Eli Lilly's Stock Is Expensive? Here's Why Selling It Now Could Be a Huge Mistake
The recent surge has been due to the tremendous growth Lilly has achieved due to its highly popular GLP-1 drugs, including ...
FiercePharma2d
Seeking fruitful Lenmeldy launch, Orchard names commercial chief to oversee world’s most expensive drug
Orchard Therapeutics has tasked Robin Kenselaar with accelerating growth of Lenmeldy, the world’s most expensive drug, ...
Super Bowl ad for Hims & Hers' weight loss drug sparks backlash
The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...
JD Supra21h
Mintz IRA Update — The Future of the Medicare Drug Price Negotiation Program
The Centers for Medicare and Medicaid Services (CMS) and pharmaceutical drug manufacturers are gearing up for the second ...
Biogen beats estimates on cost cuts and new drugs like Leqembi, but profit outlook falls short
Biogen expects Leqembi and new rare disease and depression treatments to help offset revenue lost from multiple sclerosis ...
How much longer you might live without assistance on new Alzheimer’s drugs
New drugs for early Alzheimer’s disease may allow people to live without help for up to 39 additional months, a new study estimates. But experts urge caution.
Diet drug boom weighs heavily on state budgets
The potential market for the drugs is massive — more than 40 percent of adults in the U.S. are obese — and has seen explosive growth. The number of Americans taking GLP-1s for weight loss rose more ...
Commonwealth Fund5d
Drug Costs and Their Impact on Care: Insights from Medicare Patients and Providers
Providers are sympathetic to Medicare enrollees’ concerns but don’t agree on their role in helping patients find less costly ...